Αποτελέσματα Αναζήτησης
13 Αυγ 2021 · Cutaneous lupus erythematosus (CLE) is a rare, inflammatory autoimmune skin disease with heterogeneous clinical appearance. Currently, there is no treatment specifically approved for this disease. Topical and systemic medications are used off label.
Treatment of cutaneous lupus consists of patient education on proper sun protection along with appropriate topical and systemic agents. Systemic agents are indicated in cases of widespread, scarring, or treatment-refractory disease.
30 Αυγ 2010 · In the first part of the review, topical agents and first-line systemic treatment options for cutaneous lupus erythematosus were discussed whereas in the second part, recent information on efficacy, dosage, and side effects for further systemic treatment options are described in detail.
1 Σεπ 2021 · For localized CLE lesions, topical corticosteroids and topical calcineurin inhibitors are first-line treatment. For widespread or severe CLE lesions and (or) cases resistant to topical treatment, systemic treatment including antimalarials and (or) short-term corticosteroids can be added.
Recent EULAR guideline recommended topical agents as the first-line treatment for CLE which mostly include topical corticosteroids and calcineurin inhibitors [9].
The treatment of cutaneous lupus erythematosus is centered upon formulating a regimen of topical and systemic therapies designed to reduce disease activity and minimize cosmetic damage. Sun avoidance and sunscreen are important preventative measures ...
1 Δεκ 2021 · The overall objective of the guideline is to provide up‐to‐date, evidence‐based recommendations for the management of cutaneous lupus erythematosus (CLE) in the presence or absence of systemic lupus erythematosus (SLE) in adults, young people and children.
